G
George Coukos
Researcher at Ludwig Institute for Cancer Research
Publications - 463
Citations - 49514
George Coukos is an academic researcher from Ludwig Institute for Cancer Research. The author has contributed to research in topics: Ovarian cancer & Immunotherapy. The author has an hindex of 87, co-authored 426 publications receiving 41199 citations. Previous affiliations of George Coukos include Hospital of the University of Pennsylvania & University of Glasgow.
Papers
More filters
Journal ArticleDOI
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
Eleonora Ghisoni,Matteo Morotti,Sara Colomer-Lahiguera,Manuela Eicher,George Coukos,Lionel Trueb,Massimo Di Maio +6 more
TL;DR: In this paper , the authors discuss the benefit of capturing Patient-reported outcomes (PROs) in ACT trials, the challenges of PROM administration and collection, and propose simple and actionable recommendations to promote their adoption in ACT trial.
Journal ArticleDOI
A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor.
Patrick Reichenbach,Greta Maria Paola Giordano Attianese,Elisabetta Cribioli,Melanie Triboulet,Margaux Saillard,Romain Vuillefroy de Silly,George Coukos,Melita Irving +7 more
TL;DR: In this paper , a lentiviral vector is proposed for T-cell engineering, which can facilitate the engineering of T cells that can better harness endogenous immunity and overcome suppressive barriers in the tumour microenvironment.
Patent
Heterodimeric inactivatable chimeric antigen receptors
George Coukos,Melita Irving,Bruno E. Correia,Pablo Gainza-Cirauqui,Greta Maria Paola Giordano Attianese +4 more
TL;DR: In this paper, the authors describe the use of heterodimeric inactivatable chimeric antigen receptors (CARs) and their use for treatment for treatment. But their work is limited to the treatment of cancer.
Journal ArticleDOI
42P Tumor-reactive CD8+ T cells in ovarian and colon cancer in tumors and cell products
Sara Bobisse,Blanca Navarro Rodrigo,Qui A. Ngo,Johanna Chiffelle,Raphael Genolet,Alexandra Michel,Damien Saugy,Carol A. Sauvage,David Tarussio,Marion Arnaud,Philippe Guillaume,Brett Stevenson,Michal Bassani-Sternberg,Stephanie Tissot,Sylvie Rusakiewicz,Julien Schmidt,Denarda Dangaj,Lana E. Kandalaft,George Coukos,Alexandre Harari +19 more
TL;DR: In this paper , TIL-adoptive cell transfer (ACT) only led to clinical results in a subset of patients with non-melanoma tumors, raising the question of the abundance of tumor-reactive T cells in these cancers.
Journal ArticleDOI
International Conference on Lymphocyte Engineering 31 March–2 April 2022 Munich, Germany
George Coukos,Jesus Corria-Osorio,Sanchez Carmona,Spyridon. Stefanidis,M. Andreatta,T. Muller,Yaquelin Ortiz-Miranda,Melita Irving,Paris Kosti,Giorgia Rota,Catherine Ronet,Aodrenn Spill,Bili Seijo,P. Romero,D. Laniti,L Loureiro,Rosemarie Bergmann,Robert Wodtke,F. Brandt,Claudia Arndt,Katelynn Rene Gonzalez,Nicola Mitwasi,Alexandra Kegler,Tobias Bartsch,L. Drewitz,D Mathe,A. Feldmann,Matthias Lutz-Bachmann +27 more
TL;DR: In this article , a phase I trial was conducted to evaluate the safety and efficacy of CAR-T cells and CARVAC in patients with claudin 6 (CLDN6)-positive solid tumors.